Characterizing distinct profiles of immune and inflammatory response with age to Omicron infection

Front Immunol. 2023 Jun 30:14:1189482. doi: 10.3389/fimmu.2023.1189482. eCollection 2023.

Abstract

Background: Understanding inflammatory and immune responses to Omicron infection based on age is crucial when addressing this global health threat. However, the lacking of comprehensive elucidation hinders the development of distinct treatments tailored to different age populations.

Methods: 1299 cases of Omicron infection in Shanghai were enrolled between April 10, 2022 and June 3, 2022, dividing into three groups by ages: Adult group (18-59 years), Old group (60-79 years), and Elder group (≥ 80 years). Laboratory data including inflammatory cytokines, cellular, and humoral immunity were collected and analyzed.

Results: The mean age of Adult, Old, and Elder groups were 44.14, 69.98, and 89.35 years, respectively, with 40.9% being men. The Elder group patients exhibited higher white blood cell (WBC) counts and elevated levels of inflammatory cytokines, but their lymphocyte counts were relatively lower. In comparison to the Old group patients, the Elder group patients demonstrated significantly lower CD3+ T-cell counts, CD3+ T-cell proportion, CD4+ T-cell counts, CD8+ T-cell counts, and CD19+ B-cell counts, while the NK-cell counts were higher. Omicron negative patients displayed a higher proportion of CD19+ B-cells and higher levels of Complement-3 and IL-17 compared to the positive patients in the Old group. Omicron negative patients had lower WBC counts, CD3+CD8+ T-cells proportion, and the levels of serum amyloid A and IgA in the Elder group, but the CD4+/CD8+ ratio was higher.

Conclusions: Our study identified the distinct profiles of inflammatory and immune responses to Omicron infection varying with age and highlighted the diverse correlations between the levels of various biomarkers and Omicron infected/convalescent patients.

Keywords: COVID-19; age; immunology; inflammation; omicron.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antigens, CD19
  • B-Lymphocytes*
  • CD8-Positive T-Lymphocytes*
  • China
  • Cytokines
  • Female
  • Humans
  • Killer Cells, Natural
  • Male
  • Middle Aged
  • Young Adult

Substances

  • Antigens, CD19
  • Cytokines

Grants and funding

This work was supported by the National Key Research and Development Program of China (2022YFC2009800 to ZQ) and Foundation of Shanghai Municipal Health Commission (202240204 to YL). The funders of the study had no role in the study design, data collection, analysis and interpretation, the writing of the manuscript, or the decision to submit the manuscript for publication.